The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year.
View all episodes
By BiotechTV
5
44 ratings
The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year.
30,626 Listeners
1,863 Listeners
1,085 Listeners
325 Listeners
6,059 Listeners
60 Listeners
9,840 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
497 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners